knowledge -WSS

knowledge

author：hotspot 2025-09-29 16:14:53 - browse：463

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Headspace, Meta partner to launch VR meditation app for Quest

knowledge

WSS

Study fuels hope CAR

With psoriasis trial ahead, Alumis raises $259 million

Change Healthcare payments predicted restored March 15

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

RSV shot was 90% effective at preventing hospitalizations in kids

entertainment

knowledge

hotspot

Peter Hotez and the public health issue of online harassment

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Heart attack and stroke risk calculators need revising

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

The high cost of giving birth even with insurance

Sen. Paul opposes bill to ban Chinese biotechs

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Novavax promises a turnaround & Lilly roils the obesity market

'Vaccine

focus

Ohio train derailment: Experts on toxic chemical risks

What it’s like to watch children die of measles

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Neuroscience renaissance leads to new crop of psychiatric drugs

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

hotspot

focus

knowledge

hotspot